TrialClinical and translational science2026

First-In-Human Safety, Pharmacokinetics, and Pharmacodynamics of VENT-02 Freebase, a CNS-Penetrant NLRP3 Inhibitor.

Lisanne C A Smidt et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.